跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
HEMLIBRA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
HEMLIBRA
Authorized
STANDARD
HEMLIBRA
Hoffmann-La Roche Limited
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
37d4c472ca1e0036
Company
Hoffmann-La Roche Limited
Type
Standard
Approval Details
Approval Id
37d4c472ca1e0036
Drug Approval Canada Name
HEMLIBRA
Product Name
HEMLIBRA
Status
Marketed
Status Date
2018-10-19
Original Market Date
2018-10-19
Din
02479621
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Prescription , Schedule D
Ahfs
20:28.16
Atc Original
B02BX06 EMICIZUMAB
Atc Name
b 02 bx 06
Aig Number
0160531001
Company Name
Hoffmann-La Roche Limited
Company Address
7070 Mississauga Road, Mississauga, Ontario, Canada, L5N 5M8
Active Ingredients
EMICIZUMAB
30 MG / 1 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
37d4c472ca1e0036
Type
Standard
Back to Health Canada Approvals